Differences in response to dual anti-EGFR and HER2 therapy in HNSCC in vitro and in vivo may be attributed to differences in human epidermal growth factor compensatory pathway signaling40. The gene discussed is ERBB2; the disease is head and neck squamous cell carcinoma.